Published on
Updated
Reading 1 min.
An American company has just announced the development of the very first non-hormonal injectable male contraceptive.
It’s a small revolution in the world of male contraceptives. Charlottesville, Virginia-based Contraline has announced that it has successfully tested the first-ever hydrogel-based male contraceptive implant in men (ADAM) in a clinical trial.
Four men received the contraceptive
In this trial, four men received the injectable male contraceptive.
In concrete terms, the implant was placed, without a scalpel, using an administration device that has not yet been patented.
This pose took place at the Epworth Freemasons Hospital in Melbourne.
“This is an incredible milestone in the field of urology and reproductive health. The implant procedures went extremely well.”enthusiastically reveals Nathan Lawrentschuk, director of urology in the department of urology at the Royal Melbourne Hospital and founder of the EJ Whitten Prostate Cancer Research Centre.
According to the researchers, this hydrogel “obstructs the flow of sperm through the vas deferens for a predefined period of time“.
It degrades gradually and thus offers a “temporary contraceptive optione”, unlike vasectomy – a more invasive method of male sterilization.
The only downside to the product? We do not know for the moment its duration of effectiveness or its rate of effectiveness.
But, for Kevin Eisenfrats, co-founder and CEO of Contraline: “This first male contraceptive implant is a major clinical milestone that opens up new possibilities for men who want to take contraception into their own hands”he confides before adding that the team is “looking forward to advancing ADAM (…) and bringing this product to market to transform the way people think about contraception.”